Evidence map›Paper›PMID 30906629›Full record

ArticleAmerican journal of cancer research2019

E2F1 transactivates IQGAP3 and promotes proliferation of hepatocellular carcinoma cells through IQGAP3-mediated PKC-alpha activation.

Min Lin, Yiming Liu, Xiaokun Ding, Qinjian Ke, Jieyao Shi, Zewei Ma, Hongqian Gu, Haixi Wang, Chuanfeng Zhang, Chenxi Yang and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Current genomics · 2025
    Article
  8. IQGAP3 Is an Important Mediator of Skin Inflammatory Diseases.International journal of molecular sciences · 2024
    Article
  9. Article
  10. Anti-carcinogenic effects and mechanisms of actions ofAmerican journal of cancer research · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Min LinCentral Laboratory, Sanmen People's Hospital of Zhejiang Sanmen, China.
Yiming LiuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, China.
Xiaokun DingDepartment of General Surgery, Sanmen People's Hospital of Zhejiang Sanmen, China.
Qinjian KeCentral Laboratory, Sanmen People's Hospital of Zhejiang Sanmen, China.
Jieyao ShiUrinary Surgery, Sanmen People's Hospital of Zhejiang Sanmen, China.
Zewei MaDepartment of General Surgery, Sanmen People's Hospital of Zhejiang Sanmen, China.
Hongqian GuDepartment of General Surgery, Sanmen People's Hospital of Zhejiang Sanmen, China.
Haixi WangCentral Laboratory, Sanmen People's Hospital of Zhejiang Sanmen, China.
Chuanfeng ZhangDepartment of Biochemistry and Molecular Biology, School of Medicine, Zhejiang University Hangzhou, China.
Chenxi YangCentral Laboratory, Sanmen People's Hospital of Zhejiang Sanmen, China.
Zejun FangCentral Laboratory, Sanmen People's Hospital of Zhejiang Sanmen, China.
Linfu ZhouDepartment of Biochemistry and Molecular Biology, School of Medicine, Zhejiang University Hangzhou, China.
Ming YeCentral Laboratory, Sanmen People's Hospital of Zhejiang Sanmen, China.
First People’s Hospital of Jingmen · CNJiangmen Central Hospital · CNZhejiang University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For decades, E2F1 has been recognized as a retinoblastoma protein (RB) binding transcription factor that regulates the cell cycle. E2F1 binds preferentially to RB and accelerates the cell cycle in most cancer cells. However, it is thought that E2F1 modulates cell proliferation in other ways as well. Herein, it has been discovered that in pathological tissues derived from hepatocellular carcinoma (HCC) patients, E2F1 correlates positively with IQGAP3 and that both of these factors are highly expressed (N = 164, R = 0.6716). In addition, a high level of E2F1 or IQGAP3 predicted poor survival in HCC patients. Further study determined that E2F1 transactivates IQGAP3, the GTPase binding protein in MHCC-97H cells. Co-immunoprecipitation analysis indicated that IQGAP3 interacts with PKCδ and competitively inhibits the interaction between PKCδ and PKCα, resulting in phosphorylation of PKCα activation and promotion of cell proliferation. This study reveals that highly expressed E2F1 not only transactivates cell-cycle-related factors but also promotes HCC proliferation by activating the phosphorylation of PKCα.

Indexed as

cell proliferationE2F1hepatocellular carcinomaIQGAP3PKCα activation

Identifiers

PMID30906629
PMCPMC6405983
OpenAlexW2981224316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.